Astria Therapeutics Inc ATXS:NASDAQ

Last Price$5.08NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$4.99 (6)
Ask (Size)$5.08 (6)
Day Low / HighN/A - N/A
Volume67.9 K
 

View Biotechnology IndustryPeer Comparison as of 12/03/2021

 

Astria Therapeutics Inc ( NASDAQ )

Price: $5.08
Change: -0.02 (0.39%)
Volume: 67.9 K
4:00PM ET 12/03/2021
 
 

Recro Pharma Inc ( NASDAQ )

Price: $1.40
Change: -0.07 (4.76%)
Volume: 247.3 K
4:00PM ET 12/03/2021
 
 

Genocea Biosciences Inc ( NASDAQ )

Price: $1.12
Change: -0.12 (9.68%)
Volume: 405.3 K
3:59PM ET 12/03/2021
 
 

Biocept Inc ( NASDAQ )

Price: $3.77
Change: -0.14 (3.58%)
Volume: 326.4 K
4:00PM ET 12/03/2021
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 

Read more news Recent News

--Wedbush Adjusts Astria Therapeutics' Price Target to $15 From $16, Keeps Outperform Rating
5:37AM ET 11/11/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (ATXS) ASTRIA THERAPEUTICS Posts Q3 Loss $-0.61
8:09AM ET 11/10/2021 MT Newswires

...

--Jefferies Starts Astria Therapeutics at Buy with $20 Price Target
10:33AM ET 9/29/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Oppenheimer Raises Astria Therapeutics' PT to $30 from $5 After 1 for 6 Reverse Stock Split, Keeps Outperform Rating
11:23AM ET 9/24/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionAstria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA. View company web site for more details
Address100 High Street
Boston, Massachusetts 02110
Phone+1.617.349.1971
Number of Employees24
Recent SEC Filing11/23/20214
President, Chief Executive Officer & DirectorJill C. Milne
Chief Financial OfficerNoah Clauser
Vice President-Clinical OperationsMaria C. Mancini
Chief Scientific OfficerAndrew Nichols

Company Highlights

Price Open$5.16
Previous Close$5.10
52 Week Range$4.81 - 47.82
Market Capitalization$66.1 M
Shares Outstanding13.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/10/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$23.34
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-173.67%

Analyst Ratings as of 09/28/2021

Buy
5
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset